These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30151353)

  • 1. Glioblastoma Recurrence Correlates With Increased APE1 and Polarization Toward an Immuno-Suppressive Microenvironment.
    Hudson AL; Parker NR; Khong P; Parkinson JF; Dwight T; Ikin RJ; Zhu Y; Chen J; Wheeler HR; Howell VM
    Front Oncol; 2018; 8():314. PubMed ID: 30151353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
    Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
    Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
    Jung TY; Jung S; Moon KS; Kim IY; Kang SS; Kim YH; Park CS; Lee KH
    Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas.
    Ramakrishnan V; Kushwaha D; Koay DC; Reddy H; Mao Y; Zhou L; Ng K; Zinn P; Carter B; Chen CC
    Cancer Biomark; 2011-2012; 10(3-4):185-93. PubMed ID: 22674304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
    Felsberg J; Thon N; Eigenbrod S; Hentschel B; Sabel MC; Westphal M; Schackert G; Kreth FW; Pietsch T; Löffler M; Weller M; Reifenberger G; Tonn JC;
    Int J Cancer; 2011 Aug; 129(3):659-70. PubMed ID: 21425258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quercetin induces MGMT
    Wang W; Yuan X; Mu J; Zou Y; Xu L; Chen J; Zhu X; Li B; Zeng Z; Wu X; Yin Z; Wang Q
    Phytomedicine; 2023 Sep; 118():154933. PubMed ID: 37451151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies.
    Kurdi M; Butt NS; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Dallol A; Mohamed F; Bari MO; Samkari A; Lary AI; Alkhayyat S
    J Neurooncol; 2021 May; 152(3):541-549. PubMed ID: 33661424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
    Melguizo C; Prados J; González B; Ortiz R; Concha A; Alvarez PJ; Madeddu R; Perazzoli G; Oliver JA; López R; Rodríguez-Serrano F; Aránega A
    J Transl Med; 2012 Dec; 10():250. PubMed ID: 23245659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.
    Parkinson JF; Wheeler HR; Clarkson A; McKenzie CA; Biggs MT; Little NS; Cook RJ; Messina M; Robinson BG; McDonald KL
    J Neurooncol; 2008 Mar; 87(1):71-8. PubMed ID: 18004504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
    McAleenan A; Kelly C; Spiga F; Kernohan A; Cheng HY; Dawson S; Schmidt L; Robinson T; Brandner S; Faulkner CL; Wragg C; Jefferies S; Howell A; Vale L; Higgins JPT; Kurian KM
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013316. PubMed ID: 33710615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
    Cahill DP; Levine KK; Betensky RA; Codd PJ; Romany CA; Reavie LB; Batchelor TT; Futreal PA; Stratton MR; Curry WT; Iafrate AJ; Louis DN
    Clin Cancer Res; 2007 Apr; 13(7):2038-45. PubMed ID: 17404084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of MGMT promoter methylation on the survival of TMZ treated
    Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
    Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
    Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
    Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes.
    Kessler T; Berberich A; Sadik A; Sahm F; Gorlia T; Meisner C; Hoffmann DC; Wick A; Kickingereder P; Rübmann P; Bendszus M; Opitz C; Weller M; van den Bent M; Stupp R; Winkler F; Brandes A; von Deimling A; Platten M; Wick W
    Cancer Med; 2020 Nov; 9(22):8373-8385. PubMed ID: 32991787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
    Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W
    Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of
    Jovanović N; Mitrović T; Cvetković VJ; Tošić S; Vitorović J; Stamenković S; Nikolov V; Kostić A; Vidović N; Krstić M; Jevtović-Stoimenov T; Pavlović D
    Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30717206
    [No Abstract]   [Full Text] [Related]  

  • 17. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
    Kreth S; Thon N; Eigenbrod S; Lutz J; Ledderose C; Egensperger R; Tonn JC; Kretzschmar HA; Hinske LC; Kreth FW
    PLoS One; 2011 Feb; 6(2):e17156. PubMed ID: 21365007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression.
    Zhao W; Yun K
    Exp Cell Res; 2022 Sep; 418(2):113277. PubMed ID: 35810776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
    Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
    Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative analysis of MGMT promoter methylation status changes by pyrosequencing in recurrent glioblastoma.
    Jiménez VG; Doval MB; Bellvert CG; Goliney VG; Asencio OS; Martín AG; Domínguez JI
    Neuropathology; 2023 Aug; 43(4):306-312. PubMed ID: 36504469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.